AOD9604

AOD9604 is a synthetic 16-amino-acid peptide derived from the C-terminal region of human growth hormone — specifically from amino acids 177 to 191 of the full 191-amino-acid hGH molecule — with an additional tyrosine residue added to the N-terminus. The "AOD" portion of the name stands for "Anti-Obesity Drug," reflecting the original clinical-research program that produced the molecule in the late 1990s and early 2000s. The number 9604 is an internal program identifier from that development effort. The compound is sometimes also referred to as hGH(177-191) or as the lipolytic fragment of growth hormone in older literature.

The scientific interest in AOD9604 sits at an unusual intersection of growth hormone biology and metabolic research. Full human growth hormone is a complex protein hormone with many biological roles — effects on cellular growth, on tissue maintenance, on glucose and lipid metabolism, and on the insulin / IGF-1 axis. Decades of research on growth hormone suggested that different functional activities of the molecule could be traced to different regions of the sequence. The lipolytic activity of growth hormone — its effect on fat-cell signaling and lipid metabolism — appeared in older research to be associated with the C-terminal region, particularly around amino acids 177 to 191. AOD9604 was designed to isolate this lipolytic-relevant region of the molecule as a small synthetic peptide that could be studied independently of the broader growth hormone signaling architecture.

In published research, AOD9604 has been studied as a tool for asking questions about lipolytic signaling in fat cells, the relationship between the C-terminal region of growth hormone and metabolic effects, and the possibility of a growth hormone-derived peptide that would not engage the full insulin / IGF-1 axis. The molecule advanced into clinical-research investigations in the early 2000s by Metabolic Pharmaceuticals, an Australian biotechnology company, exploring obesity-related indications. The clinical-research program did not produce an approved medicine in those indications, but the compound subsequently received recognition by the U.S. FDA as a Generally Recognized as Safe (GRAS) ingredient for use in certain food and supplement contexts in some jurisdictions — a regulatory status distinct from approval as a pharmaceutical.

This page is a plain-English educational reference for readers who want to understand what AOD9604 actually is, how it was designed and developed, what the published research describes about its biology, and where it sits in the broader research peptide landscape. It is not a medical guide, it does not describe a treatment, and it makes no claims about weight loss, fat reduction, or any other clinical effect in people. AOD9604 is a research peptide supplied for laboratory and analytical purposes only, and the entire discussion below is framed within that context.

Throughout the page, technical terms that show up repeatedly in AOD9604 research are defined when they appear. Terms like "lipolysis," "hGH(177-191)," "C-terminal fragment," "isoprenaline," and "adipocyte" appear constantly in the primary literature. The glossary at the end of the page collects all of them for easy reference, and the FAQ section addresses the questions that most often arise from students, hobbyists, and laboratory staff encountering the compound for the first time.

AOD9604 is a synthetic 16-amino-acid peptide with the sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe. The sequence corresponds to the C-terminal residues 177-191 of human growth hormone, with an additional N-terminal tyrosine residue (which is not part of the natural hGH sequence). The two cysteine residues — at positions 7 and 14 of the AOD9604 sequence, corresponding to positions 182 and 189 of the original hGH numbering — form an intramolecular disulfide bond that produces a small loop in the structure. This disulfide loop is part of the molecule's defining structural identity and reflects a corresponding loop in the parent hGH protein.

The natural hGH molecule is a 191-amino-acid protein hormone produced by the somatotroph cells of the anterior pituitary gland. It folds into a four-helix bundle structure with several disulfide bonds and acts on the growth hormone receptor (GH-R) — a class I cytokine receptor — to produce its wide range of biological effects. The C-terminal region of hGH around amino acids 177-191 forms a loop structure that is exposed on the surface of the folded protein. Older research, dating to the 1970s and 1980s, identified this region as being associated with the lipolytic activity of growth hormone — its effect on fat-cell signaling and lipid metabolism — in studies that used proteolytic fragments of the full hormone in laboratory assays.

The synthetic AOD9604 peptide was designed to capture this C-terminal lipolytic-relevant region in a small, defined, easily-produced molecule. The N-terminal tyrosine residue was added to the natural hGH(177-191) sequence in part to facilitate radio-labeling for analytical work and in part to influence the peptide's properties. The intramolecular disulfide bond between the two cysteines preserves the loop structure of the C-terminal region as it exists in the parent hGH protein. The resulting molecule has a molecular mass of approximately 1817 daltons, placing it firmly in the small-peptide range that is straightforward to produce by solid-phase peptide synthesis and to characterize by standard analytical chemistry.

The published research on AOD9604 has explored a mechanism that is conceptually distinct from full growth hormone signaling. Unlike full hGH, AOD9604 does not appear to activate the growth hormone receptor in the way the parent hormone does, and it does not appear to engage the JAK2/STAT5 signaling pathway that mediates many of full hGH's biological effects. Instead, the lipolytic activity of AOD9604 in research models appears to operate through mechanisms that involve effects on beta-adrenergic signaling and lipid metabolism in fat cells (adipocytes), without engaging the broader growth hormone / IGF-1 axis. This selectivity — lipolytic-relevant signaling without growth hormone receptor activation or IGF-1 axis engagement — has been the central scientific point of interest in the compound.

AOD9604 is produced for research use through standard solid-phase peptide synthesis using Fmoc protecting-group chemistry, with the intramolecular disulfide bond formed during oxidative folding after the linear peptide is assembled. The final product is purified by reversed-phase HPLC and characterized by mass spectrometry. It is supplied as a lyophilized powder. As a synthetic research peptide, it is intended for laboratory and analytical work — it is not a medicine or an approved therapy in any jurisdiction (its GRAS status in some food/supplement contexts is a regulatory category distinct from pharmaceutical approval).

It is worth being specific about what AOD9604 is not. It is not growth hormone — growth hormone is the much larger 191-amino-acid pituitary protein, and AOD9604 is a small 16-amino-acid fragment-derived peptide that does not appear to engage the growth hormone receptor in the way the parent hormone does. It is not a growth hormone-releasing hormone (GHRH) analog like CJC-1295 or Sermorelin, and it is not a ghrelin-receptor agonist like Ipamorelin or GHRP-2. It belongs to its own conceptual category as a designed C-terminal fragment of growth hormone with a distinct proposed mechanism.

The history of AOD9604 begins with research on the structure-function relationships of growth hormone that dates back to the 1970s. As the structure of human growth hormone became better understood and as the protein could be divided into proteolytic fragments for laboratory study, researchers began to ask whether different functional activities of the hormone could be traced to different regions of the molecule. The lipolytic activity of growth hormone — its effect on fat-cell signaling and lipid metabolism — was one of the activities investigated through this fragmentation approach.

Work in the 1970s and 1980s by several research groups identified the C-terminal region of hGH, around amino acids 177-191, as being associated with the lipolytic activity. The full hGH molecule, when administered in research models, produced both lipolytic effects and the broader insulin / IGF-1 axis effects characteristic of growth hormone signaling. Proteolytic fragments of the C-terminal region, however, reportedly produced lipolytic-relevant effects without the same magnitude of effect on the insulin / IGF-1 axis. This dissociation suggested that the C-terminal region might carry a distinct functional activity that could in principle be captured in a small synthetic peptide.

The AOD9604 program emerged from this structure-function research in the late 1990s. Metabolic Pharmaceuticals, an Australian biotechnology company, designed and developed the synthetic 16-amino-acid peptide as a candidate compound for clinical-research investigation of obesity-related indications. The "AOD" name — Anti-Obesity Drug — and the "9604" program number reflect the company's strategic positioning of the molecule. The design rationale was to capture the lipolytic-relevant C-terminal region in a small, well-characterized synthetic peptide, with the additional N-terminal tyrosine to facilitate analytical work, and with the natural intramolecular disulfide bond preserved to maintain the loop structure.

In the early-to-mid 2000s, AOD9604 advanced through clinical-research investigations exploring obesity-related indications. The studies examined various dosing schedules, measured weight and body composition endpoints, and characterized the compound's pharmacokinetic profile and tolerability. The clinical-research findings did not produce a clear weight-loss signal of sufficient magnitude to support pharmaceutical approval for obesity, and the development program for that indication was discontinued. AOD9604 did not become an approved medicine for any indication through the conventional pharmaceutical approval pathway.

In a separate regulatory development, AOD9604 received recognition by the U.S. FDA as a Generally Recognized as Safe (GRAS) ingredient for use in certain food and dietary supplement contexts in some jurisdictions. The GRAS designation is a regulatory status distinct from approval as a pharmaceutical and does not constitute approval as a medicine or as a treatment for any condition. The GRAS finding reflects a safety assessment for the specific use cases described in the GRAS notice rather than an efficacy approval.

In parallel with these regulatory developments, AOD9604 has remained available as a research peptide through specialty suppliers and has continued to appear in basic-research investigations of lipolytic signaling in adipocytes, structure-function relationships in growth hormone-derived peptides, and related metabolic research themes. Important milestones in the AOD9604 literature include the structure-function research of the 1970s and 1980s identifying the C-terminal region as lipolytic-relevant, the design and development of AOD9604 by Metabolic Pharmaceuticals in the late 1990s, the clinical-research investigations of the early-to-mid 2000s, the subsequent regulatory developments including the GRAS designation in certain contexts, and the ongoing use of the compound as a research peptide.

The science of AOD9604 is anchored in the broader biology of growth hormone, the structure-function relationships of the hGH molecule, and the specific biology of lipolytic signaling in fat cells. The compound sits at an unusual intersection of these areas, and understanding its place requires looking at each briefly.

Human growth hormone is a 191-amino-acid protein hormone produced by the somatotroph cells of the anterior pituitary gland. It folds into a characteristic four-helix bundle structure with two intramolecular disulfide bonds and acts on the growth hormone receptor — a class I cytokine receptor expressed on many cell types throughout the body. The growth hormone receptor activates the JAK2/STAT5 signaling pathway as well as other intracellular signaling cascades, producing the wide range of biological effects associated with full growth hormone signaling: effects on cellular growth, on tissue maintenance, on glucose and lipid metabolism, and on the production of insulin-like growth factor 1 (IGF-1) by the liver.

Among the diverse activities of full growth hormone, the lipolytic activity — the effect on fat-cell signaling and lipid metabolism — has been recognized for decades. Growth hormone influences fat-cell biology through several mechanisms, including effects on the activity of hormone-sensitive lipase, effects on the response of fat cells to beta-adrenergic signaling, and effects on the broader hormonal milieu that controls lipid metabolism. The lipolytic activity of full growth hormone is one of its physiological effects but is bundled together with the broader range of growth hormone signaling.

• AOD9604 is a synthetic 16-amino-acid peptide derived from the C-terminal region of human growth hormone (residues 177-191) with an N-terminal tyrosine addition.
• An intramolecular disulfide bond between cysteines at positions 7 and 14 preserves a loop structure corresponding to the parent hGH C-terminal region.
• Unlike full hGH, AOD9604 does not appear to activate the growth hormone receptor or engage the JAK2/STAT5 signaling pathway.
• Reported lipolytic-relevant activity in research models involves effects on beta-adrenergic signaling and adipocyte lipid metabolism without IGF-1 axis engagement.
• Clinical-research investigations in human obesity-related indications did not produce a clear weight-loss signal sufficient to support pharmaceutical approval.

Structurally, AOD9604 is a 16-residue cyclic peptide with the linear sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe and an intramolecular disulfide bond between the two cysteine residues at positions 7 and 14. The disulfide bond produces a small loop in the structure that mimics the corresponding loop in the parent hGH(177-191) sequence. The molecular mass of the cyclized peptide is approximately 1817 daltons, which places it in the small-peptide range that is straightforward to characterize using standard analytical chemistry techniques.

The relationship between the AOD9604 sequence and the natural hGH sequence is worth being precise about. The hGH residues 177-191 are the natural Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe sequence — 15 amino acids — corresponding to positions 2 through 16 of the AOD9604 sequence. The additional N-terminal tyrosine residue at position 1 of AOD9604 is not part of the natural hGH sequence; it was added during the design of the synthetic peptide. The N-terminal tyrosine residue is useful for analytical purposes because it provides a site for radioactive iodination (commonly used in peptide-binding assays), and it may also influence the peptide's properties in various subtle ways.

The intramolecular disulfide bond between the two cysteine residues is a key structural feature. In the natural hGH protein, the corresponding cysteines at positions 182 and 189 form a disulfide bond that stabilizes the small loop in the C-terminal region. The AOD9604 design preserves this disulfide bond, recreating the loop structure in the small synthetic peptide. Without the disulfide bond, the linear unprotected peptide would have a different conformation and likely different biological activity. The disulfide cyclization is therefore an essential structural element of AOD9604 rather than a postsynthetic modification.

These structural choices reflect a deliberate medicinal-chemistry rationale rooted in structure-function research on hGH. The C-terminal region was identified as lipolytic-relevant in older research; the loop structure was preserved through the disulfide cyclization; the small size and synthetic accessibility made the molecule a candidate for clinical-research investigation. The relationship between AOD9604 and the parent hGH protein is a clear example of a fragment-design approach in peptide medicinal chemistry.

Stability is an important consideration for any research peptide. Lyophilized AOD9604 stored sealed at deep-freeze temperatures away from light is generally considered stable for extended periods. The intramolecular disulfide bond requires care in handling — exposure to reducing conditions can break the disulfide bond and convert the cyclic peptide to the linear form with potentially altered activity. Reconstituted material in aqueous solution is typically aliquoted into single-use portions for single-use thawing to avoid repeated freeze-thaw cycles and to limit exposure to conditions that could promote disulfide scrambling or reduction.

Research-grade AOD9604 is produced through solid-phase peptide synthesis using standard Fmoc protecting-group chemistry, with particular attention to the formation of the intramolecular disulfide bond during oxidative folding after the linear peptide is assembled. Purification is by reversed-phase HPLC, and identity is verified by mass spectrometry. A Certificate of Analysis from a reputable supplier reports the sequence, the measured molecular mass, the HPLC purity percentage, and ideally also confirms the cyclic disulfide-bonded form rather than the linear reduced form.

AOD9604 has been used as a research tool across a focused set of laboratory themes, all connected to lipolytic signaling, growth hormone structure-function relationships, or the broader biology of growth hormone-derived peptides. None of the areas described below represents an established therapeutic use of AOD9604 in humans, and none should be read as suggesting clinical benefit. They are research directions where the compound has been useful as a defined experimental probe.

• Lipolytic-relevant signaling in adipocytes
• Growth hormone structure-function relationships
• Beta-adrenergic signaling research in fat cells
• Comparative metabolic peptide pharmacology
• Mechanism-of-action characterization of the C-terminal fragment

AOD9604 occupies an unusual conceptual space and is best compared with several distinct categories of compound to clarify what it is and is not. The table below highlights the key distinctions.

The most direct comparison is with full human growth hormone, from which AOD9604 is derived. Full hGH is a 191-amino-acid protein that activates the growth hormone receptor and engages the JAK2/STAT5 signaling pathway, producing the wide range of biological effects associated with growth hormone signaling — including substantial elevation of IGF-1. AOD9604, despite being derived from the C-terminal region of hGH, does not appear to activate the growth hormone receptor in the same way and does not produce the same IGF-1 elevation. The two compounds are conceptually related but pharmacologically distinct.

A separate comparison is with the GHRH analogs (CJC-1295, Sermorelin, Tesamorelin) and the GHRP / GHS-R agonists (Ipamorelin, GHRP-2, GHRP-6) that act upstream of growth hormone release from the pituitary. These compounds stimulate endogenous growth hormone release rather than mimicking or replacing growth hormone signaling directly. AOD9604 is unrelated to these upstream secretagogue approaches and operates through an entirely different proposed mechanism.

AOD9604 is also sometimes compared with other growth hormone fragment peptides studied in the historical structure-function research literature. The earlier fragments — for example, the natural unmodified hGH(177-191) sequence without the N-terminal tyrosine — share some structural and conceptual ground with AOD9604 but differ in specific design and characterization. AOD9604 is the specific modified version developed by Metabolic Pharmaceuticals.

Finally, AOD9604 should be distinguished from broader categories of metabolic-research compounds, including GLP-1 receptor agonists (Semaglutide, Liraglutide), amylin analogs (Cagrilintide), and other peptide approaches to metabolic biology. These compounds work through entirely different receptor systems and mechanisms; AOD9604 is not a member of any of these categories.

The AOD9604 literature gives a particular impression: a synthetic peptide derived from a well-characterized region of human growth hormone, developed with a clear design rationale rooted in older structure-function research, advanced through a discontinued clinical-development program in human obesity-related indications, and subsequently used as a research tool in basic-science investigations of lipolytic-relevant signaling in adipocytes. The compound's place in the broader peptide research landscape is distinct, sitting at the intersection of growth hormone biology, structure-function research, and metabolic biology.

The conceptual foundation of AOD9604 — that the C-terminal region of hGH carries lipolytic-relevant activity distinct from broader growth hormone signaling — has support in older structure-function research dating to the 1970s and 1980s. That research established the dissociation between fragment-mediated lipolytic-relevant effects and full-hormone-mediated broader effects, providing the rationale for the AOD9604 design. The published basic-research literature on AOD9604 itself has continued to refine the characterization of the compound's effects in adipocyte models and its absence of growth hormone receptor activation, supporting the dissociation rationale.

The clinical-research arc of AOD9604, however, did not produce an approved medicine in obesity-related indications. The clinical investigations in the early-to-mid 2000s by Metabolic Pharmaceuticals did not produce a clear weight-loss signal of sufficient magnitude to support pharmaceutical approval, and the development program for that indication was discontinued. The honest framing is that the basic-science rationale is well grounded in older structure-function research, the compound's effects in laboratory research models have been characterized in considerable detail, but the clinical-research investigations did not translate the laboratory findings into a clinical effect of sufficient magnitude to support approval. AOD9604 transitioned from a clinical-research candidate to a research-peptide product available through specialty suppliers, with the additional regulatory development of GRAS designation in certain food and supplement contexts.

Methodologically, AOD9604 research has used adipocyte cell-culture systems, isolated fat-cell preparations, whole-animal experiments in research models, and human clinical-research studies. The compound's pharmacokinetic profile has been characterized to a reasonable level of detail. The molecular mechanism of action, however, remains incompletely resolved and continues to be an area of investigation; the published research describes effects on beta-adrenergic signaling and adipocyte lipid metabolism without engaging the growth hormone receptor or the IGF-1 axis, but the detailed receptor and signaling targets are not fully defined.

Open questions in the field include the precise molecular target or targets of AOD9604 in adipocyte signaling, the question of why the laboratory lipolytic-relevant findings did not translate into a substantial clinical weight-loss signal in the human investigations, the broader question of how growth hormone-derived peptides relate to the parent hormone's functional architecture, and the ongoing characterization of the compound's effects in different research models.

For students, researchers, and curious readers approaching AOD9604 for the first time, the most accurate framing is that of a thoughtfully designed C-terminal hGH fragment peptide with a clear basic-science rationale, a discontinued clinical-development arc, and a continuing role as a research tool in adipocyte biology and growth hormone structure-function research. The compound is supplied for laboratory and analytical use only, and educational discussion of it needs to stay within that framing rather than drift into implied therapeutic claims or weight-loss recommendations.

AOD9604 is a synthetic 16-amino-acid peptide derived from the C-terminal region of human growth hormone (amino acids 177-191) with an additional N-terminal tyrosine residue. An intramolecular disulfide bond between two cysteine residues preserves a loop structure corresponding to the same loop in the parent hGH protein. The compound was developed by Metabolic Pharmaceuticals in the late 1990s as a candidate for clinical-research investigation of obesity-related indications, with the design rationale rooted in older structure-function research that had identified the C-terminal region of hGH as associated with the lipolytic activity of the parent hormone.

In published basic research, AOD9604 has been characterized as a peptide that does not appear to activate the growth hormone receptor in the way the parent hGH protein does, and that does not appear to produce the substantial IGF-1 elevation associated with full growth hormone signaling. Instead, the lipolytic-relevant activity observed in research models appears to involve effects on beta-adrenergic signaling and adipocyte lipid metabolism through mechanisms that are not fully resolved at the molecular level. This dissociation — lipolytic-relevant signaling without growth hormone receptor activation or IGF-1 axis engagement — has been a central feature of the AOD9604 scientific conversation.

The clinical-research arc of AOD9604 did not produce an approved medicine. The investigations in the early-to-mid 2000s in human obesity-related indications did not produce a clear weight-loss signal of sufficient magnitude to support pharmaceutical approval, and the development program for that indication was discontinued. In a separate regulatory development, AOD9604 received recognition by the U.S. FDA as a Generally Recognized as Safe ingredient for use in certain food and supplement contexts in some jurisdictions — a regulatory status distinct from pharmaceutical approval and not constituting clinical approval for any indication.

The most important educational point about AOD9604 is the gap between its basic-science rationale and its limited clinical translation. The compound has a clear structural and conceptual relationship to the parent hGH protein and has been characterized in considerable detail in laboratory research models, but the clinical-research investigations did not translate the laboratory findings into a substantial clinical effect of the type that would support pharmaceutical approval for the originally pursued indications. It is supplied as a research peptide for laboratory and analytical use only, and educational discussion of it needs to stay within that framing rather than drift into implied therapeutic claims or weight-loss recommendations.

For students, researchers, and curious readers approaching AOD9604 for the first time, the most accurate framing is that of a thoughtfully designed C-terminal hGH fragment peptide with a clear basic-science rationale, a discontinued clinical-development arc, an unusual regulatory status that includes GRAS designation in certain contexts but no pharmaceutical approval, and a continuing role as a research tool in adipocyte biology and growth hormone structure-function research.